Spotlight
Specialty
Partners
CME/CE
Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice : Episode 1
Patients With Intermediate Stage HCC Unsuitable for TACE
Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).
Now Viewing
EP: 1.Patients With Intermediate Stage HCC Unsuitable for TACE
EP: 2.Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab
EP: 3.Patients With Intermediate Stage HCC Suitable for TACE
EP: 4.HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC
EP: 5.Selecting the Appropriate Frontline Treatment in Advanced HCC
EP: 6.Other Frontline Immunotherapy-based Combinations in Advanced HCC
EP: 7.Patient Profile 2: Advanced HCC Treated with Lenvatinib
EP: 8.Real-World Evidence for Lenvatinib in Advanced HCC
EP: 9.Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab
EP: 10.Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond
Related Videos
Related Content
FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors
March 13th 2023
FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors
March 13th 2023
